Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of gantenerumab in early Alzheimer's disease
2017-001365-24Phase 3Terminated
- Sponsor
- Roche
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Gantenerumab with Placebo (2 arms). Primary endpoint: Change from baseline to Week 104 in Clinical Dementia Rating-Sum of Boxes. Started Mar 2018; status: terminated.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2017-001365-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001365-24.